The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Worrisome trends in incidence and mortality of candidemia in intensive care units (Paris area, 2002–2010)
Open accessAbstract
PURPOSE: To analyze trends in incidence and mortality of candidemia in intensive care units (ICUs) vs. non-ICU hospitalized patients and to determine risk factors for infection by specific species and for death. METHODS: Active hospital-based surveillance program of incident episodes of candidemia due to common species in 24 tertiary care hospitals in the Paris area, France between October 2002 and September 2010. RESULTS: Among 2,507 adult cases included, 2,571 Candida isolates were collected and species were C. albicans (56 %), C. glabrata (18.6 %), C. parapsilosis (11.5 %), C. tropicalis (9.3 %), C. krusei (2.9 %), and C. kefyr (1.8 %). Candidemia occurred in ICU in 1,206 patients (48.1 %). When comparing ICU vs. non-ICU patients, the former had significantly more frequent surgery during the past 30 days, were more often preexposed to fluconazole and treated with echinocandin, and were less frequently infected with C. parapsilosis. Risk factors and age remained unchanged during the study period. A significant increased incidence in the overall population and ICU was found. The odds of being infected with a given species in ICU was influenced by risk factors and preexposure to fluconazole and caspofungin. Echinocandins initial therapy increased over time in ICU (4.6 % first year of study, to 48.5 % last year of study, p < 0.0001). ICU patients had a higher day-30 death rate than non-ICU patients (odds ratio [OR] 2.12; 95 % confidence interval [CI] 1.66-2.72; p < 0.0001). The day-30 and early (<day 8) death rates increased over time in ICU (from 41.5 % the first to 56.9 % the last year of study (p = 0.001) and 28.7-38.8 % (p = 0.0292), respectively). Independent risk factors for day-30 death in ICU were age, arterial catheter, Candida species, preexposure to caspofungin, and lack of antifungal therapy at the time of blood cultures results (p < 0.05). CONCLUSIONS: The availability of new antifungals and the publication of numerous guidelines did not prevent an increase of candidemia and death in ICU patients in the Paris area.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wisplinghoff, H., Bischoff, T., Tallent, S. M., Seifert, H., Wenzel, R. P., & Edmond, M. B. (2004) · Clinical Infectious Diseases · doi:10.1086/421946 · Cited by 4,496
Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem
Pfaller, M. A., & Diekema, D. J. (2007) · Clinical Microbiology Reviews · doi:10.1128/cmr.00029-06 · Cited by 4,174 · cited 1×
“It is therefore a public health concern everywhere [5].”
BackgroundPappas, P. G., Kauffman, C. A., Andes, D., Benjamin, D. K., Calandra, T. F., Edwards, J. E., Filler, S. G., Fisher, J. F., Kullberg, B.-J., Zeichner, L. O., et al. (2009) · Clinical Infectious Diseases · doi:10.1086/596757 · Cited by 3,191 · cited 1×
“Many changes have occurred over the last decade with the availability of echinocandins, the implementation of management guidelines [9, 10], and, at least in some centers, the extended availability of new tools with improved diagnostic performances.”
BackgroundBenchmarking the Incidence and Mortality of Severe Sepsis in the United States*
Gaieski, D. F., Edwards, J. M., Kallan, M. J., & Carr, B. G. (2013) · Critical Care Medicine · doi:10.1097/ccm.0b013e31827c09f8 · Cited by 1,326
Cornely, O. A., Bassetti, M., Calandra, T., Garbino, J., Kullberg, B. J., Lortholary, O., Meersseman, W., Akova, M., Arendrup, M. C., Arikan-Akdagli, S., et al. (2012) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12039 · Cited by 1,217 · cited 1×
“Many changes have occurred over the last decade with the availability of echinocandins, the implementation of management guidelines [9, 10], and, at least in some centers, the extended availability of new tools with improved diagnostic performances.”
BackgroundSelf-citationGarey, K. W., Rege, M., Pai, M. P., Mingo, D. E., Suda, K. J., Turpin, R. S., & Bearden, D. T. (2006) · Clinical Infectious Diseases · doi:10.1086/504810 · Cited by 1,171 · cited 1×
“Although numerous other factors not captured here may have influenced the outcome, such as the delayed initiation of adequate antifungal therapy [8, 39, 40], although controversial [16], lack of consideration of antifungal dosing issues [40–42], and inadequate source control as recently emphasized [16], both the stron…”
BackgroundHorn, D. L., Neofytos, D., Anaissie, E. J., Fishman, J. A., Steinbach, W. J., Olyaei, A. J., Marr, K. A., Pfaller, M. A., Chang, C., & Webster, K. M. (2009) · Clinical Infectious Diseases · doi:10.1086/599039 · Cited by 956 · cited 1×
“2 % with an echinocandin, a percentage close to what was reported recently in the USA [7] even if more echinocandins were prescribed in one study [31].”
ResultAndes, D. R., Safdar, N., Baddley, J. W., Playford, G., Reboli, A. C., Rex, J. H., Sobel, J. D., Pappas, P. G., Kullberg, B. J., & for the Mycoses Study Group (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis021 · Cited by 793
Zaoutis, T. E., Argon, J., Chu, J., Berlin, J. A., Walsh, T. J., & Feudtner, C. (2005) · Clinical Infectious Diseases · doi:10.1086/496922 · Cited by 784
Alexander, B. D., Johnson, M. D., Pfeiffer, C. D., Jiménez-Ortigosa, C., Catania, J., Booker, R., Castanheira, M., Messer, S. A., Perlin, D. S., & Pfaller, M. A. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cit136 · Cited by 778
Cited by
Kullberg, B. J., & Arendrup, M. C. (2015) · New England Journal of Medicine · doi:10.1056/nejmra1315399 · Cited by 1,315
Azole Antifungal Resistance in Candida albicans and Emerging Non-albicans Candida Species
Whaley, S. G., Berkow, E. L., Rybak, J. M., Nishimoto, A. T., Barker, K. S., & Rogers, P. D. (2017) · Frontiers in Microbiology · doi:10.3389/fmicb.2016.02173 · Cited by 900
Changes in the epidemiological landscape of invasive candidiasis
Lamoth, F., Lockhart, S. R., Berkow, E. L., & Calandra, T. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkx444 · Cited by 547
Phosphatidylethanolamine Metabolism in Health and Disease
(2016) · International Review of Cell and Molecular Biology · doi:10.1016/bs.ircmb.2015.10.001 · Cited by 526
Incidence, characteristics and outcome of ICU-acquired candidemia in India
Chakrabarti, A., Sood, P., Rudramurthy, S. M., Chen, S., Kaur, H., Capoor, M., Chhina, D., Rao, R., Eshwara, V. K., Xess, I., et al. (2015) · Intensive Care Medicine · doi:10.1007/s00134-014-3603-2 · Cited by 454
The Changing Epidemiology of Invasive Fungal Infections
Enoch, D. A., Yang, H., Aliyu, S. H., & Micallef, C. (2017) · Methods in Molecular Biology · doi:10.1007/978-1-4939-6515-1_2 · Cited by 370
Morbidity and mortality of candidaemia in Europe: an epidemiologic meta-analysis
Koehler, P., Stecher, M., Cornely, O. A., Koehler, D., Vehreschild, M. J. G. T., Bohlius, J., Wisplinghoff, H., & Vehreschild, J. J. (2019) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2019.04.024 · Cited by 336
The global burden of fungal diseases
Vallabhaneni, S., Mody, R. K., Walker, T., & Chiller, T. (2016) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2015.10.004 · Cited by 292
Arastehfar, A., Carvalho, A., Nguyen, M. H., Hedayati, M. T., Netea, M. G., Perlin, D. S., & Hoenigl, M. (2020) · Journal of Fungi · doi:10.3390/jof6040211 · Cited by 272
Candidemia and invasive candidiasis in adults: A narrative review
Antinori, S., Milazzo, L., Sollima, S., Galli, M., & Corbellino, M. (2016) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2016.06.029 · Cited by 257
Timsit, J.-F., Azoulay, E., Schwebel, C., Charles, P. E., Cornet, M., Souweine, B., Klouche, K., Jaber, S., Trouillet, J.-L., Bruneel, F., et al. (2016) · JAMA · doi:10.1001/jama.2016.14655 · Cited by 198
“Results of the primary end point regarding various predefined subgroups of interest are reported in Figure 2 for the modified ITT population (with HRs substantially favoring the micafungin group for patients with [1-3]-β-D-glucan levels >80 pg/mL, [1-3]-β-D-glucan levels of 250 pg/mL, Candida scores at ≥3, and coloniz…”
Self-citationEmerging multidrug-resistant Candida species
Colombo, A. L., Júnior, J. N. D. A., & Guinea, J. (2017) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000000411 · Cited by 177
Astvad, K. M. T., Johansen, H. K., Røder, B. L., Rosenvinge, F. S., Knudsen, J. D., Lemming, L., Schønheyder, H. C., Hare, R. K., Kristensen, L., Nielsen, L., et al. (2018) · Journal of Clinical Microbiology · doi:10.1128/jcm.01564-17 · Cited by 125
The Cava Trem Study Group, León, C., Ruiz-Santana, S., Saavedra, P., Castro, C., Loza, A., Zakariya, I., Úbeda, A., Parra, M., Macías, D., et al. (2016) · Critical Care · doi:10.1186/s13054-016-1324-3 · Cited by 110
Self-citationSystemic antifungal therapy for proven or suspected invasive candidiasis: the AmarCAND 2 study
Leroy, O., Bailly, S., Gangneux, J.-P., Mira, J.-P., Devos, P., Dupont, H., Montravers, P., Perrigault, P.-F., Constantin, J.-M., Guillemot, D., et al. (2016) · Annals of Intensive Care · doi:10.1186/s13613-015-0103-7 · Cited by 102
Self-citationThe current treatment landscape: Candidiasis
Bassetti, M., Peghin, M., & Timsit, J.-F. (2016) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkw392 · Cited by 99
Azole Resistance in Candida glabrata
Whaley, S. G., & Rogers, P. D. (2016) · Current Infectious Disease Reports · doi:10.1007/s11908-016-0554-5 · Cited by 85
Pfaller, M. A., Messer, S. A., Rhomberg, P. R., Borroto-Esoda, K., & Castanheira, M. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00161-17 · Cited by 84
Dellière, S., Healey, K., Gits-Muselli, M., Carrara, B., Barbaro, A., Guigue, N., Lecefel, C., Touratier, S., Desnos-Ollivier, M., Perlin, D. S., et al. (2016) · Frontiers in Microbiology · doi:10.3389/fmicb.2016.02038 · Cited by 75
Self-citationRiera, F. O., Caeiro, J. P., Angiolini, S. C., Vigezzi, C., Rodriguez, E., Icely, P. A., & Sotomayor, C. E. (2022) · Antibiotics · doi:10.3390/antibiotics11070877 · Cited by 65
“Compared with FLZ AFST, echinocandin AFST is used less frequently, which is predictable because echinocandin AFST is not recommended for all bloodstream isolates [89].”
BackgroundNing, Y., Xiao, M., Perlin, D. S., Zhao, Y., Lu, M., Li, Y., Luo, Z., Dai, R., Li, S., Xu, J., et al. (2023) · Emerging Microbes & Infections · doi:10.1080/22221751.2022.2153086 · Cited by 63
“Indeed, approximately 35% to 51% of invasive candidiasis (IC) cases occurred in intensive care units (ICU), resulting in a mortality rate between 40% and 51% [1,2].”
In vitro Antifungal Effects of Berberine Against Candida spp. In Planktonic and Biofilm Conditions
Xie, Y., Liu, X., & Zhou, P. (2020) · Drug Design, Development and Therapy · doi:10.2147/dddt.s230857 · Cited by 63
Baldesi, O., Bailly, S., Ruckly, S., Lepape, A., L'Heriteau, F., Aupee, M., Boussat, S., Bervas, C., Machut, A., Berger-Carbonne, A., et al. (2017) · Journal of Infection · doi:10.1016/j.jinf.2017.03.011 · Cited by 60
The epidemiology of Candida species in the Middle East and North Africa
Ghazi, S., Rafei, R., Osman, M., El Safadi, D., Mallat, H., Papon, N., Dabboussi, F., Bouchara, J.-P., & Hamze, M. (2019) · Journal de Mycologie Médicale · doi:10.1016/j.mycmed.2019.07.006 · Cited by 50
Desnos-Ollivier, M., Lortholary, O., Bretagne, S., & Dromer, F. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02615-20 · Cited by 44
Self-citationSharma, V., Purushotham, R., & Kaur, R. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.751529 · Cited by 22
Burden of serious fungal infections in Ukraine
Osmanov, A., & Denning, D. W. (2015) · Mycoses · doi:10.1111/myc.12409 · Cited by 20
Desnos-Ollivier, M., Bretagne, S., Lortholary, O., Dromer, F., & the French Mycoses Study Group N. Brieu CH Aix, T. C. (2022) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01725-21 · Cited by 13
Self-citation
Metadata
- Authors
- The French Mycosis Study Group, Lortholary, O., Renaudat, C., Sitbon, K., Madec, Y., Denoeud-Ndam, L., Wolff, M., Fontanet, A., Bretagne, S., & Dromer, F.
- Venue
- Intensive Care Medicine
- Published
- 2014-08-06
- Volume
- 40
- Issue
- 9
- Pages
- 1303-1312
- ISSN
- 0342-4642 (ISSN-L)
- 1432-1238
- OpenAlex
- W1970856277
- Cited by
- 312
- References
- 43
- FWCI
- 24.23
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.